Mandate

Vinge has advised Nordea Bank AB (publ) (“Nordea”) in connection with a tender offer and issue of new bonds with an aggregate transaction value of SEK 2,705,000,000

October 03, 2018 Banking and Finance

Vinge has advised Nordea Bank AB (publ) (“Nordea”) in connection with a tender offer and issue of new bonds with an aggregate transaction value of SEK 2,705,000,000.

Vinge has advised Nordea in connection with Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) tender offer and subsequent repurchase of its previously issued senior and unsecured bonds up to a total amount of SEK 1,205,000,000 (the “Tender Offer”) and its issuance of new senior unsecured bonds with a framework amount of up to SEK 1,500,000,000 (the “New Bonds”).

The initial amount issued under the New Bonds amounts to SEK 1,000,000,000 per 3 October 2018. Nordea was mandated as sole arranger, bookrunner and issuing agent in connection with the New Bonds and as dealer manager, sole bookrunner and tender agent in relation to the Tender Offer.

The New Bonds have a tenor of four years and carry a floating rate interest of STIBOR 3M + 3.60%.

Vinge’s team consisted of Mikael Ståhl, Josefine Larsson and Lionardo Ojeda.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025